Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December ...

A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from ...

HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...

Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They ...

Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD ...

Analysts have set 12-month price targets for ACADIA Pharmaceuticals, revealing an average target of $25.0, a high estimate of $28.00, and a low estimate of $20.00. A 2.91% drop is evident in the ...